Showing 37–48 of 81 results
Histone modifications are essential in eukaryotic gene expression and regulation, and are driven by histone writer, eraser, and reader proteins.…
Read MoreReady-to-Use qualified PathHunter® checkpoint bioassays are fit-forpurpose for potency testing for implementation in downstream development phases and Lot release of…
Read MoreIt is well established that ligand binding can protect proteins from thermal denaturation in a cellular milieu; however, the broad…
Watch NowHere we will describe InCELL Pulse™, which uses DiscoverX’s Enzyme Fragment Complementation (EFC) technology to overcome these limitations of current…
Watch NowMonoclonal antibodies (MAbs) represent one of the fastest growing classes of biotherapeutic molecules today. While many technologies exist for generating…
Read MoreBiologics represents one of the fastest growing classes of biopharmaceutical molecules today. One of the major bottlenecks in the development…
Read MoreDrug efficacy and cellular target engagement studies have traditionally been monitored by evaluation of downstream cellular responses, such as detection…
Read MoreA common feature of 7TM receptors is that upon activation, the receptors are bound by cellular Arrestin proteins. DiscoveRx has…
Read MoreFollowing the recent regulatory approvals of a number of checkpoint inhibitor therapeutics, development of a wide array of immunomodulatory therapeutic…
Read MoreCell-based bioassays often pose a hurdle during a rapidly moving biologics development program. High standards for assay accuracy, precision, reproducibility…
Read MoreOne of the major bottlenecks in the development of biosimilars is the need for good bioassays to create potency, stability…
Read MoreLigand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional read-out for Interleukin receptors.…
Read More
